Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jushi HoldingsJUSHF -0.25%51 Debt-to-EBITDA is 10.33 as of Mar. 2026, which is 159% above its 10-year median of 3.99. GuruFocus rates JUSHF with a GF Score™ of 51/100 and a GF Value™ of $0.51 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 689 Drug Manufacturers companies, Jushi Holdings ranks worse than 90.57% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Jushi Holdings's Debt-to-EBITDA or its related term are showing as below:
JUSHF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.64 Med: 3.99 Max: 9.85
Current: 8.4
During the past 13 years, the highest Debt-to-EBITDA Ratio of Jushi Holdings was 9.85. The lowest was -2.64. And the median was 3.99.
JUSHF's Debt-to-EBITDA is ranked worse than 90.57% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs JUSHF: 8.40
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Jushi Holdings Debt-to-EBITDA Related Terms
Jushi Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Jushi Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jushi Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jushi Holdings Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jushi Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Jushi Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Jushi Holdings (JUSHF) has a Debt-to-EBITDA of 10.33 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Jushi Holdings. This is 159% above median its historical median of 3.99. According to the industry distribution chart, Jushi Holdings ranks #624 out of 689 companies in the Drug Manufacturers industry, placing it in the top 90.6%.
Is Jushi Holdings' Debt-to-EBITDA too high?
Jushi Holdings' current Debt-to-EBITDA of 10.33 is 159% above median its 10-year median of 3.99. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Jushi Holdings' value of 10.33 is 514.9% above this industry median. Based on the distribution chart, Jushi Holdings ranks #624 out of 689 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jushi Holdings has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jushi Holdings' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jushi Holdings ranks #624 out of 689 companies for Debt-to-EBITDA. This places Jushi Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Jushi Holdings' value of 10.33 is 514.9% above this benchmark. While the company's 10-year median is 3.99 vs. the industry median of 1.68, Jushi Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jushi Holdings's current Debt-to-EBITDA of 10.33 is 514.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Jushi Holdings. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jushi Holdings's current Debt-to-EBITDA is 10.33, which is 159% above median its own 10-year median of 3.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jushi Holdings stock overvalued right now?
Based on GuruFocus' analysis, Jushi Holdings (JUSHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.51, compared to a current price of $0.40 — trading 21.5% below its estimated fair value. The current Debt-to-EBITDA is 10.33, which is 159% above median its 10-year median of 3.99 and 514.9% above the Drug Manufacturers industry median of 1.68. Jushi Holdings' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Jushi Holdings (JUSHF), the current Debt-to-EBITDA is 10.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jushi Holdings (JUSHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jushi Holdings stock appears to be undervalued.
The current stock price of $0.40 is trading 21.5% below its estimated GF Value™ of $0.51.
GuruFocus considers Jushi Holdings to be Modestly Undervalued.
Key valuation signals for JUSHF:
Debt-to-EBITDA: 10.33 (159% above median its 10-year median of 3.99)
GF Value™: $0.51 vs. price of $0.40 (21.5% below fair value)
Industry Position: 514.9% above the Drug Manufacturers median (#624 of 689)
No single metric tells the full story. See the JUSHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jushi Holdings Inc is a vertically integrated multi-state cannabis and hemp operator engaged in retail, distribution, cultivation, and processing in both medical and adult-use markets. The company operates a diverse portfolio of branded cannabis and hemp-derived assets built upon opportunistic acquisitions, distressed deals, and competitive applications. Its products are offered through brands like Hijinks, The Bank, The Lab, Seche, and Tasteology, among others. The company distributes its products through various retail dispensaries, including Nature's Remedy, Beyond Hello, and NuLeaf, and also operates an e-commerce platform called The Jushi Shop, offering branded apparel, accessories, and other products of its different brands. All of its revenues are generated within the United States.
51GF Score
Get the complete analysis for JUSHF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JUSHF has been successfully added to your 
